A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)-Reference-Cited by-同舟云学术

A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)

Published:2011-03 Issue:3 Volume:120 Page:454-458
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Herzog Thomas J.,Sill Michael W.,Walker Joan L.,O'Malley David,Shahin Mark,DeGeest Koen,Weiner Sheldon A.,Mutch David,DeBernardo Robert L.,Lentz Samuel S.

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference27 articles.

1. Cancer statistics, 2009;Jemal;CA Cancer J Clin,2009

2. Preclinical profile of SK&F 104864, a water soluble analogue of campothecin;Rowinsky,1989

3. Current perspectives in the treatment of ovarian cancer: an update on the role of topotecan;Herzog;Oncologist,2002

4. Clinical experience with topotecan in relapsed ovarian cancer;Herzog;Gynecol Oncol,2003

5. Topotecan versus paclitaxel for the treatment or recurrent ovarian cancer;Ten Bokkel Huinink;J Clin Oncol,1997

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of cisplatin combined with vinorelbine as second- or higher-line palliative chemotherapy in patients with advanced ovarian cancer;Medicine;2023-03-17

2. A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer;British Journal of Cancer;2020-09-30

3. Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy;Medicine;2020-04

4. Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041);Gynecologic Oncology;2019-01

5. Multiline treatment combining apatinib with toptecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases;OncoTargets and Therapy;2018-04